BMI-Related Prescription Costs (2014 Chinese yuan) a, b.

Clinical Input Variables.

Summary results of meta-analysis and indirect treatment comparison.

Annual direct medical costs for diabetes-related events and adverse events (2015 Chinese value).

Annual Direct Medical Costs for Diabetes-Related Complications (2014 Chinese Yuan).

Demographics and risk factors.

Demographic and Risk Factors.

Utility decrements.

Base case results for dapagliflozin arm versus acarbose arm.

Sensitivity analyses results for dapagliflozin arm versus acarbose arm (results per patient).

Body mass index (BMI) -related costs a (2015 Chinese value).

ObjectiveThis study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes...

Annual treatment costs for different drugs (2015 Chinese value).

Annual Treatment Costs (2014 Chinese yuan).

Base Case Results for Saxagliptin plus Metformin Compared with Acarbose plus Metformin (2014 Chinese yuan).

Clinical input variables.